scholarly article | Q13442814 |
P50 | author | John Rex | Q67918633 |
P2093 | author name string | M Lozano-Chiu | |
M D Martins | |||
P2860 | cites work | Antiretroviral effect of zidovudine-didanosine combination on blood and lymph nodes | Q40913624 |
P433 | issue | 5 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | candidiasis | Q273510 |
Candida albicans | Q310443 | ||
P304 | page(s) | 1291-1294 | |
P577 | publication date | 1998-11-01 | |
P1433 | published in | Clinical Infectious Diseases | Q5133764 |
P1476 | title | Declining rates of oropharyngeal candidiasis and carriage of Candida albicans associated with trends toward reduced rates of carriage of fluconazole-resistant C. albicans in human immunodeficiency virus-infected patients | |
P478 | volume | 27 |
Q34335250 | A clinical perspective for the management of invasive fungal infections: focus on IDSA guidelines. Infectious Diseases Society of America |
Q46758165 | A randomized study of the use of fluconazole in continuous versus episodic therapy in patients with advanced HIV infection and a history of oropharyngeal candidiasis: AIDS Clinical Trials Group Study 323/Mycoses Study Group Study 40. |
Q34594076 | Antifungal drug resistance of pathogenic fungi. |
Q34807486 | Antifungal drug resistance to azoles and polyenes |
Q34335225 | Antifungal resistance among Candida species |
Q34492756 | CD8+ T cells but not polymorphonuclear leukocytes are required to limit chronic oral carriage of Candida albicans in transgenic mice expressing human immunodeficiency virus type 1. |
Q48163274 | Candida glabrata Biofilms: How Far Have We Come? |
Q40539777 | Candida species diversity and antifungal susceptibility patterns in oral samples of HIV/AIDS patients in Baja California, Mexico |
Q34505582 | Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America |
Q34936576 | Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. |
Q34993877 | Clinical relevance of mechanisms of antifungal drug resistance in yeasts |
Q35633925 | Comparison of the epidemiology, drug resistance mechanisms, and virulence of Candida dubliniensis and Candida albicans |
Q34423476 | Defective IL-17- and IL-22-dependent mucosal host response to Candida albicans determines susceptibility to oral candidiasis in mice expressing the HIV-1 transgene |
Q51716718 | Diagnosis and Management of Candida and Other Fungal Infections of the Head and Neck. |
Q42224074 | Evaluation of efficacy, pharmacokinetics and tolerability of peptidomimetic aspartic proteinase inhibitors as cream formulation in experimental vaginal candidiasis |
Q34490092 | Fluconazole for the management of invasive candidiasis: where do we stand after 15 years? |
Q27318203 | Gain of function mutations in CgPDR1 of Candida glabrata not only mediate antifungal resistance but also enhance virulence |
Q36238025 | Genetic variation of innate immune genes in HIV-infected african patients with or without oropharyngeal candidiasis. |
Q33859215 | Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004). |
Q35920633 | Immunopathogenesis of oropharyngeal candidiasis in human immunodeficiency virus infection. |
Q37333439 | Macrophage-mediated responses to Candida albicans in mice expressing the human immunodeficiency virus type 1 transgene |
Q36900988 | Mouse model of oropharyngeal candidiasis |
Q35782813 | Mucosal and systemic fungal infections in patients with AIDS: prophylaxis and treatment |
Q38363105 | Opportunistic yeast pathogens: reservoirs, virulence mechanisms, and therapeutic strategies |
Q34041589 | Oral Candida isolates colonizing or infecting human immunodeficiency virus-infected and healthy persons in Mexico |
Q34521587 | Oral lesions of HIV disease and HAART in industrialized countries |
Q34303424 | Oropharyngeal Candida colonization in human immunodeficiency virus infected patients |
Q33746435 | Oropharyngeal candidiasis in the era of antiretroviral therapy |
Q34992078 | Persistence of oropharyngeal Candida albicans strains with reduced susceptibilities to fluconazole among human immunodeficiency virus-seropositive children and adults in a long-term care facility |
Q46656032 | Point prevalence, microbiology and antifungal susceptibility patterns of oral Candida isolates colonizing or infecting Mexican HIV/AIDS patients and healthy persons. |
Q33894467 | Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America |
Q34569070 | Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences |
Q36821383 | The use of caspofungin in HIV-infected individuals |
Q37180338 | Therapy and prophylaxis of opportunistic infections in HIV-infected patients: a guideline by the German and Austrian AIDS societies (DAIG/ÖAG) (AWMF 055/066) |
Q42002376 | Transcriptional landscape of trans-kingdom communication between Candida albicans and Streptococcus gordonii. |
Q44322984 | Treatment of opportunistic infections among adult and adolescent patients infected with the human immunodeficiency virus in the era of highly active anti-retroviral therapy |
Q34085884 | Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. |
Q43785347 | Two-year surveillance on fluconazole susceptibility of Candida spp isolates in a general and university hospital in Rome |
Q37060341 | Will resistance in fungi emerge on a scale similar to that seen in bacteria? |
Search more.